- 
				Laboratory Performance of the DopaFuse® Delivery System
- 
				Lack of Notable Skin Reactions from a Novel Levodopa/Carbidopa Prodrug after 10 Days of Repeated 24-Hour Continuous Subcutaneous Infusion at the Same Administration Site
- 
				Language characteristics of picture description task by Hebrew speaking patients with Parkinson’s disease
- 
				Language disorders in Progressive Supranuclear Palsy: an underestimated condition?
- 
				Large Sample Study on Paroxysmal Kinesigenic Dyskinesia: Genotype-Phenotype Analysis and Diagnosis Recommendations
- 
				Late onset idiopathic cerebral edema associated with deep brain stimulation
- 
				LATE ONSET OF PARKINSON’S DISEASE
- 
				Left STN DBS And Right CZI DBS In A Patient With Tremor-Predominant Parkinson’s Disease
- 
				Levocarb-induced diplopia in idiopathic Parkinson’s disease: a case report
- 
				Levodopa Effects on Visuospatial Working Memory in Parkinson’s Disease
- 
				Levodopa Induced dyskinesia in patients with Parkinson’s disease and polymorphisms gene DRD3 dopamine receptor
- 
				Levodopa response in later stages of Parkinson’s disease: a case-control study
- 
				Levodopa-carbidopa intestinal gel infusion: a video analysis of long-term effect on gait and posture
- 
				Levodopa-responsive tremor in a young child as a delayed complication of osmotic demyelination from severe hypernatremia
- 
				Levodopa/carbidopa Intestinal Gel in Treatment of Non-Motor Symptoms in Advanced Parkinson’s Disease
- 
				Life expectancy with and without Parkinson’s disease in the general population
- 
				Limitations of Curcumin as a Therapeutic Agent in Rotenone Induced Dopaminergic Neurodegeneration: Insights from Drosophila Model of Parkinson’s Disease
- 
				Lip movement contribution in speech production of persons with Parkinson’s Disease
- 
				Liquid Levodopa/Carbidopa – An underutilized, cost effective treatment of advanced Parkinson’s disease in the developing world
- 
				Local anesthesia vs general anesthesia in STN-dDBS operation: a clinical comparison of the outcome of patients with advanced Parkinson’s disease
- 
				Local beta band synchronization predicts clinically-selected deep brain stimulation contact in Parkinson’s disease patients
- 
				Local field potential recordings in the human pallidum using externalized directional DBS leads
- 
				Long term evolution of ventilatory function in Parkinson’s disease
- 
				Long Term Follow Up Following Multidisciplinary Inpatient Rehabilitation for Functional Movement Disorders
- 
				Long term outcome of STN-DBS for Parkinson Disease patients using Directional mode setting programs
- 
				Long-term adherence with wearing a multi-sensor watch in the Personalized Parkinson Project
- 
				Long-term apomorphine infusion (APO) users versus short-term APO users: What is the reason to discontinue therapy? A multi-centre study
- 
				Long-term changes in myocardial sympathetic innervation and function in synucleinopathies
- 
				Long-term effect of levodopa-carbidopa intestinal gel on axial signs in Parkinson’s disease
- 
				Long-term effects of bilateral subthalamic nucleus stimulation on sleep in patients with Parkinson’s disease
- 
				Long-Term Effects of LPS and Alcohol in Rats: A Model of Neuro-Degenerative Disease
- 
				Long-term follow up of unilateral focused ultrasound subthalamotomy for the treatment of motor features in asymmetric PD
- 
				Long-term impact of Levodopa Carbidopa Intestinal Gel (LCIG) on reducing “Off” time: Results from a systematic review of studies with ≥ 12 months of follow-up
- 
				Long-term levodopa-carbidopa intestinal infusion in Parkinson’s disease: survival and mortality
- 
				Long-term Motor and Non-motor Outcomes in Parkinson’s Disease Following Deep Brain Stimulation
- 
				Long-Term Outcomes in Patients with Tardive Dyskinesia who Were Early Responders with Valbenazine
- 
				Long-Term Outcomes with Valbenazine 40 mg/day in Adults with Tardive Dyskinesia
- 
				Long-term safety and efficacy of apomorphine infusion in Parkinson’s disease (PD) patients with persistent motor fluctuations: results of the 1-year open-label phase of the TOLEDO study
- 
				Long-term safety and efficacy of rimabotulinumtoxinB in the treatment of adult sialorrhea
- 
				Long-term treatment of cervical dystonia with abobotulinumtoxinA
- 
				Long-Term Treatment With Deutetrabenazine Is Associated With Continued Improvement in Tardive Dyskinesia: Results From an Open-Label Extension Study
- 
				Long-term Yearly Trends of Feeding Tube Placement in Neurodegenerative Disorders
- 
				Longitudinal analysis of disease progression in a large PKAN cohort in the Dominican Republic
- 
				Longitudinal Analysis of the Corticospinal tract microstructure in Parkinson’s Disease Patients
- 
				Longitudinal analysis of the modified Hoehn and Yahr disease stage in PD-1101, a Phase 1b clinical study of VY-AADC01
- 
				Longitudinal analysis of the relation between trajectories of dopaminergic agonists use and BMI in Parkinson’s disease
- 
				Longitudinal assessment of genetic determinants of cognitive decline in Parkinson’s disease
- 
				Longitudinal Change of Substantia Nigra Hyperechogenicity in Parkinson’s Disease Cohort
- 
				Longitudinal Cortical Changes Associated with Apathy in Parkinson’s Disease
- 
				Longitudinal CSF-profile and brain pathology mirrors clinical course of LRRK2-Related Parkinson’s Disease
- 
				Longitudinal digital observation of the holistic quality of the life of patients with Parkinson’s disease
- 
				Longitudinal DNA methylation changes, in blood, associated with Parkinson’s disease progression
- 
				Longitudinal progression of spatiotemporal parameters of turning in idiopathic Parkinson’s disease patients with Freezing of Gait
- 
				Longstanding cervical dystonia followed by parkinsonism – coincidence, risk factor or syndromic association?
- 
				Looking “cherry red spot myoclonus” in the eyes
- 
				Low and high beta band activity in the primary sensorimotor cortex is diminished by ipsilateral subthalamic stimulation in Parkinsonian patients
- 
				Low doses of scopolamine exacerbates dementia among Drosophila with Parkinson’s disease pathophysiology
- 
				Lower urinary tract symptoms and urodynamic findings in SCAs
- 
				LRP10 variants and Parkinson’s disease in the Chinese population
- 
				LY-341,495, an mGlu2/3 antagonist, abolishes the anti-dyskinetic and anti-psychotic effects of the mGlu2/3 orthosteric agonist LY-354,740 in the MPTP-lesioned marmoset
- 
				Lymphocyte Senescence in Parkinson’s Disease
2019 International Congress
September 22-26, 2019. Nice, France.
